Your browser doesn't support javascript.
loading
Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis.
Schwarz, Carsten; Eschenhagen, Patience; Schmidt, Henrijette; Hohnstein, Thordis; Iwert, Christina; Grehn, Claudia; Roehmel, Jobst; Steinke, Eva; Stahl, Mirjam; Lozza, Laura; Tikhonova, Ekaterina; Rosati, Elisa; Stervbo, Ulrik; Babel, Nina; Mainz, Jochen G; Wisplinghoff, Hilmar; Ebel, Frank; Jia, Lei-Jie; Blango, Matthew G; Hortschansky, Peter; Brunke, Sascha; Hube, Bernhard; Brakhage, Axel A; Kniemeyer, Olaf; Scheffold, Alexander; Bacher, Petra.
Afiliação
  • Schwarz C; Klinikum Westbrandenburg, Campus Potsdam, Cystic Fibrosis Section, Potsdam, Germany.
  • Eschenhagen P; Klinikum Westbrandenburg, Campus Potsdam, Cystic Fibrosis Section, Potsdam, Germany.
  • Schmidt H; Institute of Clinical Molecular Biology, Christian-Albrecht University of Kiel, Kiel, Germany.
  • Hohnstein T; Institute of Immunology, Christian-Albrecht University of Kiel and UKSH Schleswig-Holstein, Kiel, Germany.
  • Iwert C; Department of Microbiology, Infectious Diseases and Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Grehn C; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Translational Immunology, Berlin, Germany.
  • Roehmel J; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Steinke E; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt - Universität zu Berlin, Berlin, Germany.
  • Stahl M; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Lozza L; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt - Universität zu Berlin, Berlin, Germany.
  • Tikhonova E; German Center for Lung Research (DZL), associated partner site, Berlin, Germany.
  • Rosati E; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Stervbo U; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt - Universität zu Berlin, Berlin, Germany.
  • Babel N; German Center for Lung Research (DZL), associated partner site, Berlin, Germany.
  • Mainz JG; Cell Biology Laboratory, Precision for Medicine GmbH, Berlin, Germany.
  • Wisplinghoff H; Institute of Clinical Molecular Biology, Christian-Albrecht University of Kiel, Kiel, Germany.
  • Ebel F; Institute of Immunology, Christian-Albrecht University of Kiel and UKSH Schleswig-Holstein, Kiel, Germany.
  • Jia LJ; Institute of Clinical Molecular Biology, Christian-Albrecht University of Kiel, Kiel, Germany.
  • Blango MG; Institute of Immunology, Christian-Albrecht University of Kiel and UKSH Schleswig-Holstein, Kiel, Germany.
  • Hortschansky P; Center for Translational Medicine and Immune Diagnostics Laboratory, Marien Hospital Herne, University Hospital of the Ruhr University Bochum, Herne, Germany.
  • Brunke S; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Hube B; Center for Translational Medicine and Immune Diagnostics Laboratory, Marien Hospital Herne, University Hospital of the Ruhr University Bochum, Herne, Germany.
  • Brakhage AA; Brandenburg Medical School/Medizinische Hochschule Brandenburg (MHB), University, Pediatric Pulmonology/Cystic Fibrosis, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany.
  • Kniemeyer O; Labor Dr. Wisplinghoff, Cologne, Germany.
  • Scheffold A; Institute for Virology and Microbiology, Witten/Herdecke University, Witten, Germany.
  • Bacher P; Institute for Infectious Diseases and Zoonoses, LMU, Munich, Germany.
J Clin Invest ; 133(5)2023 03 01.
Article em En | MEDLINE | ID: mdl-36701198
ABSTRACT
BACKGROUNDThe fungus Aspergillus fumigatus causes a variety of clinical phenotypes in patients with cystic fibrosis (pwCF). Th cells orchestrate immune responses against fungi, but the types of A. fumigatus-specific Th cells in pwCF and their contribution to protective immunity or inflammation remain poorly characterized.METHODSWe used antigen-reactive T cell enrichment (ARTE) to investigate fungus-reactive Th cells in peripheral blood of pwCF and healthy controls.RESULTSWe show that clonally expanded, high-avidity A. fumigatus-specific effector Th cells, which were absent in healthy donors, developed in pwCF. Individual patients were characterized by distinct Th1-, Th2-, or Th17-dominated responses that remained stable over several years. These different Th subsets target different A. fumigatus proteins, indicating that differential antigen uptake and presentation directs Th cell subset development. Patients with allergic bronchopulmonary aspergillosis (ABPA) are characterized by high frequencies of Th2 cells that cross-recognize various filamentous fungi.CONCLUSIONOur data highlight the development of heterogenous Th responses targeting different protein fractions of a single fungal pathogen and identify the development of multispecies cross-reactive Th2 cells as a potential risk factor for ABPA.FUNDINGGerman Research Foundation (DFG), under Germany's Excellence Strategy (EXC 2167-390884018 "Precision Medicine in Chronic Inflammation" and EXC 2051-390713860 "Balance of the Microverse"); Oskar Helene Heim Stiftung; Christiane Herzog Stiftung; Mukoviszidose Institut gGmb; German Cystic Fibrosis Association Mukoviszidose e.V; German Federal Ministry of Education and Science (BMBF) InfectControl 2020 Projects AnDiPath (BMBF 03ZZ0838A+B).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aspergilose Broncopulmonar Alérgica / Fibrose Cística Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Clin Invest Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aspergilose Broncopulmonar Alérgica / Fibrose Cística Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Clin Invest Ano de publicação: 2023 Tipo de documento: Article